The system evaluation of DDP and fluorouracil in the nasopharyngeal carcinoma.

Lin Meng*, Mingming Yang**, Xingde Tian, Bi Qiang

Department of Otolaryngology Head and Neck Surgery, the First People’s Hospital of Jingzhou, PR China

*These authors contributed equally to this work

Abstract

Objective: To discuss the therapeutic effects of DDP and fluorouracil in Nasopharyngeal Carcinoma (NPC).

Methods: 40 patients with NPC who were treated in our hospital from January 2014 to August 2017 were chosen as the research objects and divided into two groups in line with the random number table. 40 patients in the control group were treated with the concurrent radiochemotherapy and 40 patients in the observation group were treated with DDP+fluorouracil (PF) combining with concurrent radiochemotherapy. Therapeutic effects, distant metastasis, local recurrence, five-year survival rate and untoward effects of patients in both groups were observed.

Results: 34 patents had Complete Remission (CR) and 5 patients had Partial Remission (PR) in the observation group. The total control ratio was 97.5%. There were 26 patients with CR and 7 patients with PR in the control group. The total control ratio was 82.5%, P<0.05. Five-year OS and PFS in the observation group were 87.5% and 85%, respectively and those of the control group were 75% and 82.5%, respectively, P<0.05. The occurrence of nausea and vomiting and leukocyte ↓ of patients in both groups had the significant difference, P<0.05. There was no significant difference in other untoward effects, P>0.05.

Conclusions: PF scheme concurrent radiochemotherapy significantly improved local control ratio of NPC and obviously enhanced five-year survival rate of patients, but untoward effects in the therapeutic process should be noticed to ensure curative effects.

Keywords: DDP, Fluorouracil, Nasopharyngeal carcinoma (NPC), Concurrent radiochemotherapy.
before 1 month prior treatment; women in gestation period or lactating women; patients with history of serious cardiopulmonary disease. According to the random number table, these patients were divided into two groups. There were 29 male patients and 11 female patients in 40 patients of the observation group, which had the age of 48-76 y old and mean age of (52.75 ± 10.48 y old). There were 30 male patients and 10 female patients in 40 patients of the control group, which had the age of 45-75 y old and (51.68 ± 9.27 y old). Both patients had no obvious difference in general data, P>0.05.

**Therapeutic methods**

Patients in the control group were treated with the radiotherapy and patients in the observation group were treated with PF combining with concurrent radiochemotherapy.

**Radiation methods:** All patients were treated with IMRT. A thermoplastic film cover of the head, neck and shoulder was used to fix patients. CT scanning method was applied to scan from patients’ head to the clavicle for 2 cm. The depth of stratum was 3.3 cm. The protective area was sketched. MRI enhancement scan and CT enhancement were used to scan and display the lump of patients in the nasopharynx. The prescription dosage in the target volume was set up as follows: GTVnx (nasopharynx lesion volume) 70-76 Gy, GTVnd (cervical lymph node lymphatic metastasis) 61-66 Gy, CTV1 (tumor target volume 1) 70 Gy, CTV2 54 Gy. After segmenting for 30 times, Varian 2300C linear accelerator 6 MV X-ray was used to irradiate from the uniform or non-uniform angles, with the conventional segmentation, 2 Gy/times, 5 times/w.

**Chemotherapy regimens:** PF scheme was applied, DDP 80 mg/m², mixture 50 ml normal saline, and d1 intravenous drip. Hydration was required before 1 d of pharmacy; 5 FU 500 mg/m², mixture 500 ml normal saline, d1-5 intravenous drip; 1times at the interval of 3 w. When patients had the serious untoward effects in the therapeutic process, dosage should be reduced. The reduced dosage was 20% of initial dosage. After adjustment, if there were serious untoward effects, patients should stop therapy. Patients in both groups should be treated for 2 periods.

**Observational indexes**

Therapeutic effects, distant metastasis, local recurrence, five-year survival rate and untoward effects of patients in both groups were observed.

**The criteria of curative effects:** According to WHO solid tumor’s therapeutic evaluation, CR was judged: complete disappearance of tumor and no new lesion for more than 4 w; PR: by comparing with the pre-treatment, GTVnx was reduced by more than 50% and no new lesion for more than 4 w; SD (stability): by comparing with the pre-treatment, GTVnx was reduced by 50% or below or it was increased by no more than 25%, and no new lesion for more than 4 w; PD (progression): by comparing with the pre-treatment, GTVnx was increased by more than 25% or had new lesions or had lesion metastasis. Tumor control ratio=(CR+PR)/total patients × 100%.

Toxic and side effects should be evaluated in line with NCI toxicant classification standard 3.0 version [4].

Five-year survival rate included overall survival and Progression-Free Survival (PFS).

**Statistical methods**

SPSS20.0 was applied to record, analyse and dispose. Measurement data were expressed as (x ̄ ± s), t-test; enumeration data were presented in n, χ² test; p<0.05 showed that there was the statistical difference.

**Results**

**Untoward effects of patients in both groups in treatment process**

The occurrence of nausea and vomiting and leukocyte ↓ of patients in both groups had the significant difference, P<0.05. Other untoward effects had no significant difference, P>0.05, shown in Table 1.

<table>
<thead>
<tr>
<th>Untoward effects</th>
<th>Observation group (n=40)</th>
<th>Control group (n=40)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I</td>
<td>II</td>
<td>III</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>19</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Blood platelet ↓</td>
<td>12</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Leukocyte ↓</td>
<td>5</td>
<td>11</td>
<td>20</td>
</tr>
<tr>
<td>Hemoglobin ↓</td>
<td>6</td>
<td>13</td>
<td>7</td>
</tr>
<tr>
<td>Glutamic-pyruvic transaminase</td>
<td>7</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Urea nitrogen</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Oral mucositis</td>
<td>10</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td>Radiodermatitis</td>
<td>19</td>
<td>12</td>
<td>5</td>
</tr>
</tbody>
</table>
Clinical effects of patients in both groups

There were 34 patients with CR and 5 patients with PR in the observation group. The total control ratio was 97.5%. There were 26 patients with CR and 7 patients with PR in the control group. The total control ratio was 82.50%, P<0.05, Table 2.

Table 2. Clinical effects of patients in both groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Cases</th>
<th>CR</th>
<th>PR</th>
<th>SD</th>
<th>PD</th>
<th>Total control ratio (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observation group</td>
<td>40</td>
<td>34</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>97.5</td>
</tr>
<tr>
<td>Control group</td>
<td>40</td>
<td>26</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>82.5</td>
</tr>
</tbody>
</table>

$\chi^2$ /  4.267  0.392  2.883  2.051  12.500

P /  0.039  0.531  0.090  0.152  0.000

One-year and five-year survival rates of patients in both groups

One-year OS and PFS in the observation group were 92.5% and 90%, respectively and those of the control group were 90% and 85%, respectively. Five-year OS and PFS in the observation group were 87.5% and 85%, respectively and those of the control group were 75% and 82.5%, respectively, P<0.05, Table 3.

Table 3. One-year and five-year survival rates in both groups.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Cases</th>
<th>One-year survival rate (%)</th>
<th>Five-year survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>OS</td>
<td>PFS</td>
</tr>
<tr>
<td>Observation group</td>
<td>40</td>
<td>92.5</td>
<td>90.0</td>
</tr>
<tr>
<td>Control group</td>
<td>40</td>
<td>90.0</td>
<td>85.0</td>
</tr>
</tbody>
</table>

$\chi^2$ /  0.391  1.143  5.128  4.669

P /  0.532  0.285  0.024  0.031

Discussions

NPC has the relatively higher sensitivity to radiotherapy and chemotherapy. The five-year survival rate of pure radiotherapy was only 67-77% [5], so inducing chemotherapy combining with the concurrent radiochemotherapy is standard and widely applied treatment mode.

This study indicated that there were 34 patients with CR and 5 patients with PR in the observation group. The total control ratio was 97.50%. There were 26 patients with CR and 7 patients with PR in the control group. The total control ratio was 82.50%, P<0.05. Five-year OS and PFS in the observation group were 87.5% and 85%, respectively and those of the control group were 75% and 82.5%, respectively, P<0.05. The occurrence of nausea and vomiting and leucocyte ↓ of patients in both groups had the significant difference, P=0.05. Other untoward effects had no significant difference, P>0.05.

Concurrent radiochemotherapy can reduce death possibility of NPC patients by 40-53% [6], because the local control ratio can be effectively enhanced. Meanwhile, it can reduce distant metastasis and increase radiosensitivity. PF scheme is the most extensive scheme in clinical NPC inducing chemotherapy and it is a recommended drug in concurrent radiochemotherapy of NPC. Inducing chemotherapy neoadjuvant chemotherapy is the chemotherapy before radical radiation therapy [7]. Through the concurrent radiochemotherapy, the cytotoxic effect in new drugs can reduce tumor, improve anoxia of engine body, promote synchronization of cell cycles, enhance radiosensitivity, show the interference or inhibiting effect on the sublethal cell injury of tumor cells, so as to develop the synergistic effects on the radiotherapy or even wipe out the subclinical metastatic lesion. Moreover, chemical toxicity in treatment won’t generate the superposition effects with radiation toxicity, reduce the radiotherapy toxicity, and effectively improve local control ratio of NPC. Inducing chemotherapy has no obvious research results on improving the patients’ survival rate. Some researchers think that inducing chemotherapy can significantly enhance patients’ five-year disease free survival [8]. Some researchers also think that it can significantly improve patients’ total survival rate and disease free survival [9,10]. Concurrent radiochemotherapy will increase toxic and side effects, while enhancing patients’ local control ratio and survival rate. Reduction of leucopenia and nausea and vomiting are two common untoward effects. In the treatment process, it is necessary to reinforce symptomatic treatment to ensure the therapeutic effects. With the progress of the target treatment, some scholars combine concurrent radiochemotherapy with the targeted drug, thus the treatment will be more accurate. This reduces the toxic and side effects, while improving the curative effects.

To some up, PF scheme concurrent radiochemotherapy significantly improved local control ratio of NPC and obviously enhanced five-year survival rate of patients, but untoward effects in the therapeutic process should be noticed to ensure curative effects.

References


*Correspondence to*

Mingming Yang
Department of Otolaryngology Head and Neck Surgery
The First People’s Hospital of Jingzhou
PR China